Quantum Biopharma (QNTM) EBT (2019 - 2026)

Quantum Biopharma has disclosed EBT across 8 years of filings, most recently posting -$3.0 million for Q1 2026.

• EBT for Q1 2026 came in at -$3.0 million, up 13.34% year-over-year; the trailing twelve-month figure through Mar 2026 was -$15.2 million (down 15.68% YoY), and the FY2025 annual result was -$15.5 million, up 4.38% from the prior year.
• EBT came in at -$3.0 million for Q1 2026 at Quantum Biopharma, down from -$2.5 million in the prior quarter.
• In the past five years, EBT ranged from a high of $25.3 million in Q2 2023 to a low of -$9.8 million in Q1 2023.
• The 5-year median for EBT is -$3.4 million (2023), against an average of -$1.4 million.
• Across the five-year window, EBT plunged 274.88% in 2023 and jumped 76.95% in 2024, its largest moves.
• Quantum Biopharma's EBT stood at $5.6 million in 2022, then tumbled by 227.7% to -$7.2 million in 2023, then soared by 70.88% to -$2.1 million in 2024, then slipped by 20.93% to -$2.5 million in 2025, then retreated by 17.18% to -$3.0 million in 2026.
• The last three EBT figures came in at -$3.0 million (Q1 2026), -$2.5 million (Q4 2025), and -$4.8 million (Q3 2025), per Business Quant data.